Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm willing to wait if the results are good (defined as sufficient to get FDA approval).
I think it's very encouraging to see Pluristem proceed with the clinical work. It does seem to indicated that they've seen nothing to discourage them from proceeding. This is good, given the doubt created by the very slow progress in Covid testing.
It's also interesting to speculate that even as other therapeutics are coming on line, the PLX cell's more natural and specific "as needed" response may be superior in the long run. "Titrate to need" on a cellular and molecular level is something that monocloal antibodies cannot do.
True, I noticed that analysts always have a very "conservative" estimate. We have two blockbusters in the pipe, very close to the finishing line, I would go with Jesspro's numbers.
Agree!! I think Jess is much closer, for both... I'd go much higher.
Sounds like we have "capitulation" on this board! They say that's a good sign. I'm looking for a move up!
Given the need, it is quite stunning that it's taking this long to determine if PLX is useful in treating Covid complications. This is especially frustrating given the solid indications of the possibility, not just with PLX but others getting similar results with stem cell therapy. The administrative state is deadly!
Thanks for the clarification!
The EAP is in fact more significant in expanding the scope of use. I am however puzzled by the 100 limit. Maybe the idea is that Pluristem should be able to show significant benefit outside the highly regulated clinical trial, and thus will be eligible for reconsideration after the 100 th patient treated. That's my optimistic and unsubstantiated hope,
Regards,
zzaatt.
The news this AM is a reminder of a couple of things:
1. Agony, ecstacy, joy, despair, as seen on this board on a daily basis is unwarranted. As I keep saying, we are in the dark on specific corporate strategy and ongoing negotiations with companies, government agencies, medical institutions, etc.. News happens suddenly, and changes things, either decisively or in some less decisive but definitive direction. Which brings me to today:
2. The fact that Pluristem has been given the opportunity to provide PLX-PAD on a compassionate basis means, at the very least, that there are officials who think it's worth a try, and that the scientists/physicians working in/with Pluristem believe that there is sufficient evidence at this point, such that they will in fact show sufficient efficacy to make PLX-PAD a valuable therapeutic tool. Certainly enough for me to get a warm cozy feeling about the prospects of PLX-PAD in Covid 19.
Excellent analysis!
Word gets out (esp. among physicians in the front lines).
My hope is that good results with Covid will:
1. Legitimize the whole stem cell approach (which is still in the "exotic" category).
2. Provide overall credibility to Pluristem specifically. We should be able to show that our much vaunted production/distribution capability is quite real.
3. Give our valuation a very significant boost. If the technology works as we expect, our current valuation is insanely low.
The next month or two should move us very close to these goals.
Interesting article! The biotech sector will be doing very well in the next few months, even as PSTI is getting ready to release (hopefully) good clinical data. That should have a nice multiplier effect on the valuation.
Greggors, you managed to tickle bio-rese's funny bone. Good work. He needs something to cheer him up. He seems to "fear" something or other most of the time.